Document Detail

Sildenafil citrate increases fetal weight in a mouse model of fetal growth restriction with a normal vascular phenotype.
Jump to Full Text
MedLine Citation:
PMID:  24204949     Owner:  NLM     Status:  MEDLINE    
Fetal growth restriction (FGR) is defined as the inability of a fetus to achieve its genetic growth potential and is associated with a significantly increased risk of morbidity and mortality. Clinically, FGR is diagnosed as a fetus falling below the 5(th) centile of customised growth charts. Sildenafil citrate (SC, Viagra™), a potent and selective phosphodiesterase-5 inhibitor, corrects ex vivo placental vascular dysfunction in FGR, demonstrating potential as a therapy for this condition. However, many FGR cases present without an abnormal vascular phenotype, as assessed by Doppler measures of uterine/umbilical artery blood flow velocity. Thus, we hypothesized that SC would not increase fetal growth in a mouse model of FGR, the placental-specific Igf2 knockout mouse, which has altered placental exchange capacity but normal placental blood flow. Fetal weights were increased (by 8%) in P0 mice following maternal SC treatment (0.4 mg/ml) via drinking water. There was also a trend towards increased placental weight in treated P0 mice (P = 0.056). Additionally, 75% of the P0 fetal weights were below the 5(th) centile, the criterion used to define human FGR, of the non-treated WT fetal weights; this was reduced to 51% when dams were treated with SC. Umbilical artery and vein blood flow velocity measures confirmed the lack of an abnormal vascular phenotype in the P0 mouse; and were unaffected by SC treatment. (14)C-methylaminoisobutyric acid transfer (measured to assess effects on placental nutrient transporter activity) per g placenta was unaffected by SC, versus untreated, though total transfer was increased, commensurate with the trend towards larger placentas in this group. These data suggest that SC may improve fetal growth even in the absence of an abnormal placental blood flow, potentially affording use in multiple sub-populations of individuals presenting with FGR.
Mark Robert Dilworth; Irene Andersson; Lewis James Renshall; Elizabeth Cowley; Philip Baker; Susan Greenwood; Colin Peter Sibley; Mark Wareing
Related Documents :
573439 - Exocrine ductal pco2 in the rabbit pancreas.
22445459 - Energetic recovery in porcine grafts by minimally invasive liver oxygenation.
2868599 - Ablation of serotonergic nerves in the rat pancreas. lack of effects on hormone secreti...
1129679 - The influences of changes in temperature on intestinal lymph flow and relationship to o...
24875909 - The effects of prenatal exposure to low-level cadmium, lead and selenium on birth outco...
16781679 - Pancreatic vasoconstrictor responses are regulated by neurons in the rostral ventrolate...
18853589 - Evaluation of an oxford miniature vaporizer placed in-circuit during the maintenance ph...
11778079 - Effects of different concentrations of anticoagulant on the in vitro characteristics of...
11139189 - Pretreatment of whole blood for use in immunochromatographic assays for hepatitis b vir...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2013-10-30
Journal Detail:
Title:  PloS one     Volume:  8     ISSN:  1932-6203     ISO Abbreviation:  PLoS ONE     Publication Date:  2013  
Date Detail:
Created Date:  2013-11-08     Completed Date:  2014-08-05     Revised Date:  2014-11-05    
Medline Journal Info:
Nlm Unique ID:  101285081     Medline TA:  PLoS One     Country:  United States    
Other Details:
Languages:  eng     Pagination:  e77748     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Flow Velocity / drug effects
Disease Models, Animal
Fetal Development / drug effects*
Fetal Growth Retardation / drug therapy*,  metabolism
Fetal Weight / drug effects*
Fetus / blood supply,  drug effects*,  metabolism
Insulin-Like Growth Factor II / metabolism
Mice, Knockout
Phosphodiesterase Inhibitors / pharmacology
Piperazines / pharmacology*
Placenta / blood supply,  metabolism
Purines / pharmacology
Sulfones / pharmacology*
Umbilical Arteries / metabolism
Uterine Artery / metabolism*
Grant Support
G0802770//Medical Research Council; G0802770/92495//Medical Research Council
Reg. No./Substance:
0/Phosphodiesterase Inhibitors; 0/Piperazines; 0/Purines; 0/Sulfones; 3M7OB98Y7H/sildenafil; 67763-97-7/Insulin-Like Growth Factor II

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): PLoS One
Journal ID (iso-abbrev): PLoS ONE
Journal ID (publisher-id): plos
Journal ID (pmc): plosone
ISSN: 1932-6203
Publisher: Public Library of Science, San Francisco, USA
Article Information
Download PDF
Copyright: 2013 Dilworth et al
Received Day: 24 Month: 5 Year: 2013
Accepted Day: 6 Month: 9 Year: 2013
collection publication date: Year: 2013
Electronic publication date: Day: 30 Month: 10 Year: 2013
Volume: 8 Issue: 10
E-location ID: e77748
PubMed Id: 24204949
ID: 3813774
Publisher Id: PONE-D-13-21228
DOI: 10.1371/journal.pone.0077748

Sildenafil Citrate Increases Fetal Weight in a Mouse Model of Fetal Growth Restriction with a Normal Vascular Phenotype Alternate Title:Sildenafil Citrate in a Mouse Model of FGR
Mark Robert Dilworth12*
Irene Andersson3
Lewis James Renshall12
Elizabeth Cowley12
Philip Baker4
Susan Greenwood12
Colin Peter Sibley12
Mark Wareing12
Lynette Kay Rogersedit1 Role: Editor
1Maternal and Fetal Health Research Centre, Institute of Human Development, University of Manchester, Manchester, United Kingdom
2Manchester Academic Health Science Centre, St. Mary’s Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom
3Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada
4Liggins Institute, University of Auckland, Auckland, New Zealand
The Ohio State Unversity, United States of America
Correspondence: * E-mail:
[conflict] Competing Interests: The authors have declared that no competing interests exist.
Contributed by footnote: Conceived and designed the experiments: MRD PNB SLG CPS MW. Performed the experiments: MRD IJA LJR EC. Analyzed the data: MRD IJA MW. Wrote the paper: MRD SLG CPS MW.


Fetal growth restriction (FGR) is defined as a baby that fails to reach its genetic growth potential and affects approximately 5–10% of pregnancies worldwide [1]. FGR places a baby at a significantly increased risk of being stillborn whilst babies that survive are more likely to present with childhood morbidities such as cerebral palsy [2]. Additionally, strong correlations exist between low birth weight and an increased risk of adulthood diseases such as hypertension, diabetes mellitus and stroke [3][5]. The major cause of FGR is thought to be placental dysfunction [6].

Despite the significant risks associated with FGR-affected pregnancies, there remains no treatment. The only option currently available to clinicians is early delivery of the baby which is itself associated with increased morbidity and/or mortality [7], [8]. Furthermore, there are still no drugs developed specifically for obstetric conditions currently in clinical trials [9]. This has led to the assessment of drugs currently used in clinical practice for other diseases, to be assessed on a re-purpose basis as potential therapeutics in the treatment of FGR.

Sildenafil citrate (SC, Viagra™), initially used as a treatment for pulmonary hypertension and now established as a treatment for erectile dysfunction [10], represents one such potential therapy. SC is a phosphodiesterase 5 (PDE-5) inhibitor, delaying the breakdown of cyclic guanosine monophosphate (cGMP) and enhancing nitric oxide (NO)-dependent vasodilatation. SC has been shown to restore ex vivo myometrial artery dilatation from FGR-affected pregnancies [11]. There have now been a number of studies investigating SC as a potential treatment for FGR [12], with a consensus on its effectiveness yet to be reached. SC has been shown to be effective in a mouse model that demonstrates FGR, the catechol-o-methyl transferase (COMT) knockout mouse, where fetal weight was normalized following SC treatment in the final third of pregnancy [13]. In this study, the COMT knockout mouse also demonstrated an abnormal umbilical artery Doppler waveform, a clinical feature in some cases of human FGR, with reduced end diastolic blood flow velocity; this too was normalized following treatment with SC [13]. In a sheep model of FGR induced by maternal nutrient restriction, long-term (from day 28–115 of pregnancy) SC treatment increased both fetal growth and amino acid availability in the conceptus [14]. However, a separate study, also in sheep, in which FGR was induced by ligation of a single uterine artery (causing placental infarction and thus placental insufficiency), demonstrated that acute (24-hour) administration of SC resulted in a decreased uterine artery blood flow [15]. In addition, SC treatment in this study resulted in fetal tachycardia and hypotension, with the authors urging caution regarding the use of SC in pregnancy [15]. In a recent study in which FGR was elicited in the rat by maternal administration of the nitric oxide synthase blocker Nω-Nitro-l-arginine Methyl Ester (L-NAME), it was suggested that SC reduced the number of stillbirth pups but also reduced fetal weight [16]. Despite these concerns, a recent non-randomised clinical trial tested the effectiveness of SC as a treatment in severe early-onset FGR [17] and showed an increase in abdominal circumference of these fetuses compared with an untreated severe early onset FGR group [17].

For these studies listed above, the rationale of SC treatment was that it would improve fetal growth by normalising or increasing uteroplacental blood flow. However, a significant proportion of pregnancies identified as FGR do not present clinically with a vascular phenotype (i.e. abnormal uterine artery or umbilical artery blood flow velocity as assessed by Doppler ultrasound) [18][21]. Thus, the question remains as to whether any future SC therapy should only be targeted to those pregnancies with abnormal uterine/umbilical artery Doppler flow-velocity waveforms.

In order to address this question, we employed a mouse model of FGR that does not demonstrate an abnormal uteroplacental vascular phenotype. The model chosen was the placental-specific insulin-like growth factor 2 (Igf2) P0 knockout mouse, hereafter referred to as P0. These mice demonstrate a reduction in placental size from embryonic day (E) 12.5, prior to the ensuing FGR first seen at E 16.5 [22], [23]. This timeline suggests that the observed FGR in the P0 knockout mouse is a result of placental insufficiency. Placentas from P0 mice demonstrate abnormal morphology, and are characterized by an increased thickness and reduced surface area of the exchange barrier within the labyrinthine (maternofetal exchange) layer, associated with a decreased permeability to hydrophilic solutes [24]. This abnormal morphology and exchange barrier function of the P0 placenta is similar to that in placentas from FGR-affected human pregnancies [25], [26]. However, in vitro myography data suggest that there is no placental vascular defect in these mice [27].

The aim of our study was therefore to test the null hypothesis that SC would fail to increase fetal weight in the P0 knockout mouse because of this lack of an abnormal vascular phenotype.

Materials and Methods

Experiments were performed in accordance with the UK Animals (Scientific Procedures) Act of 1986 under Home Office licence 40/3385. The Local Ethical Review Process of the University of Manchester approved all protocols. When required, anaesthesia was employed to minimise pain and suffering.

Placental specific Igf2 (Delta U2 P0) knockout mice, which had deletion of the U2 exon of the Igf2 gene, were generated as previously described [28] and were a kind gift from Professor W. Reik and Dr M Constância (Babraham Institute, Cambridge, UK).

Wild type C57Bl/6J female mice (10 to 16 weeks old) and males heterozygous for the P0 deletion (10 weeks to 6 months old) were mated and embryonic day 0.5 of gestation (E 0.5) determined by the discovery of a copulation plug (term = E 19.5). This cross resulted in both WT and P0 pups within a single litter. All animals were provided with nesting material and housed in cages maintained under a constant 12 h light/dark cycle at 21–23°C with free access to food (Beekay Rat and Mouse Diet, Bantin & Kingman, Hull, UK) and water.

On E12.5, animals were randomly assigned into either control or treated groups. Those in the treated group were given 0.4 mg/ml sildenafil citrate (SC; Pfizer, Sandwich, UK), via drinking water, until E18.5 with a fresh bottle made up at E15.5. Control animals remained on standard drinking water. 0.4 mg/ml SC was chosen despite previous studies demonstrating positive effects at a concentration of 0.2 mg/ml [13], [29]. This was because, in the original study [29], the authors were attempting to achieve a dose of SC of 50 mg/kg/d. However, early monitoring of P0 mice suggested average drinking of 3–4 ml of water per mouse per day; 0.2 mg/ml SC dosage would only achieve 24–32 mg/kg/day for a 25 g mouse at E12.5. Hence, a decision was made to increase this dose to 0.4 mg/ml to achieve a therapeutic dose closer to 50 mg/kg/d. This compares with a dose of around 1–2 mg/kg/day previously administered in human pregnancy [17] and reviewed in [12], although caution should be taken when making direct comparisons between species given the faster rate at which SC is metabolized in the mouse versus human [30].

In total, 23 control and 19 SC-treated mice were used. From these, mice were either assigned to a group for measurement of umbilical artery/vein blood flow velocity or a group for those undergoing placental clearance/transport studies. Study design can be seen in Figure 1. At E18.5, dams were euthanised and fetuses and placentas were blotted and weighed. In a subset of mice where radioactivity had not been used (14 control and 11 SC-treated mice) fetal anthropomorphic measurements (crown:rump length, abdominal circumference and head circumference) were taken as previously described [31]. Fetal tail tips were collected from all mice for analysis of genotype.

Fetal Weight Frequency Distribution Curves

Fetal weight histograms were constructed as previously described [32] and a non-linear regression performed (Gaussian distribution). The 5th percentile weight was calculated as: (−Z critical value × SD)+mean

where Z critical value (for the 5th centile) = 1.645 and SD = standard deviation.


Fetuses were genotyped using genomic DNA extracted from fetal tail tips (DNeasy, Qiagen, Crawley, UK). Igf2 P0 mutants were identified via an established PCR method using a primer pair to amplify a 740 bp fragment across the 5 kb deletion (sense, [gene: 5′-TCCTGTACCTCCTAACTACCAC -3′]; antisense, [gene: 5′-GAGCCAGAAGCAAACT -3′]) with a third primer amplifying a 495 bp fragment from the WT allele ([gene: 5′- CAATCTGCTCCTGCCTG-3′]), as described previously [33]. PCR conditions are available upon request.

Umbilical Artery and Vein Blood Flow Velocity

We performed in vivo assessment of umbilical blood flow using ultrasound biomicroscopy in order to confirm the lack of a vascular defect in P0 mice. Minimal and maximal blood flow velocities in umbilical artery and vein were assessed at E 18.5 as described previously [13]. Briefly, mice were anaesthetized with isofluorane (3%) in air, with maternal heart rate, respiratory temperature and rectal temperature being recorded throughout. Following hair removal around the abdomen, pre-warmed gel was applied to the skin. Mice were imaged transcutaneously using an ultrasound biomicroscope (Vevo 2100, Visualsonics®, Toronto, Canada) and a 30 MHz transducer operating at 100 frames/s. In color Doppler mode, the high-pass filter was set at 6 Hz and the pulse repetition frequency was set between 4 and 48 kHz. A 0.2 to 0.5 mm pulsed Doppler gate was used, and the angle between the Doppler beam and the vessel was <30°. Images were then recorded for offline analysis. Peak (maximal) systolic velocity (PSV) and end (minimal) diastolic velocity (EDV) were measured from at least 3 cardiac cycles that were not affected by motion caused by maternal breathing and the results were averaged. The pulsatility index (PI) was calculated as PI = (PSV-MDV)/MV where PSV = peak systolic velocity, MDV = minimum diastolic velocity and MV = mean (time-averaged) velocity.

Unidirectional Maternofetal Clearance of 14C-MeAIB Across the Intact Placenta (MeAIBKmf)

The activity of the placental System A transporter is reduced in human FGR [34], [35] and is first upregulated then reduced at the time FGR is observed in the P0 mouse [22]. We therefore investigated whether SC had any effect on transfer of amino acid via this transporter by measuring the clearance across the placenta of 14C-methylaminoisobutyric acid (MeAIB), a non-metabolisable substrate for system A. MeAIBKmf across the intact placenta was measured at E 18.5 using an adaptation of the method of Flexner and Pohl [36] as described previously [23]. Following infusion of 14C-MeAIB, exsanguination of the dam occurred between 1 and 5 minutes post-infusion in accordance with previous studies [23], [37]. Fetuses were rapidly collected and assessed for total radiolabel accumulation and compared to a maternal plasma 14C-MeAIB disappearance curve (see below).

MeAIBKmf (µl/min/g placenta) was calculated as:

[Formula ID: pone.0077748.e001]
Where, Nx = total radiolabel accumulation (dpm) by the fetus (corrected for the fetal tail tip retained for genotyping) at x min after injection of radiolabel into the maternal vein, W = placental wet weight (g) and  = the time integral of radioisotope concentration in maternal plasma (dpm.min/µl) from 0 to x min (taken from the maternal plasma 14C-MeAIB disappearance curve).

Maternal Plasma 14C-MeAIB Disappearance Curve Following Injection into the Maternal Circulation

A maternal plasma 14C-MeAIB disappearance curve was constructed from dams at E 18.5 (N = 51) and fitted to a one-phase exponential decay model (r2>0.6) as described previously [37]. These 51 dams consisted of the 16 dams in this study together with historical data from C57 dams (crossed with P0 males) from our research group. Disappearance curves were checked to ensure that dams in this study gave comparable values to historical data and that SC did not alter maternal plasma 14C-MeAIB disappearance.

Data and Statistical Analyses

Sample sizes were determined using Altman’s nonogram based upon a 5% significance level and 80% statistical power. All data were normally distributed following a D’Agostino & Pearson normality test and are shown as mean ± SEM. Unless otherwise stated, a Generalized Linear Mixed Models approach, with each litter used as a random effect, was used to assess whether there was a significant effect of genotype and/or treatment. A Sequential Sidak multiple comparisons test was then used to test for differences between groups. P<0.05 was deemed statistically significant. Statistical analyses were performed using IBM SPSS Statistics software (IBM, New York, US).

Fetal and Placental Weights and Fetal Anthropometric Measurements

Litter size was not significantly affected by SC treatment (8.0±0.2 in control versus 8.6±0.3 fetuses per litter in SC, unpaired t test), nor did SC treatment affect the proportion of WT and P0 pups within a litter (52% of pups were WT in both water and SC-treated litters). Fetal and placental weights are shown in Figure 2. Fetal weight (Fig. 2A) was significantly lower in P0 versus WT, independent of treatment (P<0.001). Treatment with SC caused an increase in P0 fetal weight (expressed as Mean ± SEM, grams) compared with water-treated P0 mice (1.02±0.02 treated versus 0.94±0.02 untreated, P<0.05) with WT weights unaffected by treatment (1.25±0.02 treated versus 1.20±0.03 untreated). Fetal weight frequency distribution curves (Fig. 2B) demonstrated that 49% of P0 fetuses treated with SC were above the 5th centile of the untreated WT weights compared with 25% in the untreated P0 group. Placental weight (Fig. 2C) was decreased in P0 versus WT, which was independent of treatment (P<0.001). SC treatment failed to increase placental weight in WT mice (0.097±0.002 treated versus 0.092±0.002 untreated) with P0 placental weight higher but just failing to reach statistical significance at the 5% level following SC treatment (0.072±0.002 treated versus 0.065±0.002 untreated, P = 0.056). The fetal:placental (F:P) weight ratio was increased in P0 versus WT, independent of treatment (P<0.001) but was not altered following SC treatment in either WT (13.1±0.3 untreated versus 13.2±0.4 treated or P0 (14.4±0.4 treated versus 15.0±0.3 untreated) mice.

Crown:rump length (P<0.001), abdominal circumference (P<0.001) and head circumference (P<0.05) were all significantly reduced in P0 versus WT, independent of treatment (Table 1). SC treatment failed to alter either crown:rump length or head circumference in WT or P0 mice but did increase abdominal circumference in both WT (P<0.01) and P0 (P<0.05) pups.

Umbilical Artery and Vein Blood Flow Velocity

Umbilical artery minimal and maximal velocities and pulsatility index (Fig. 3A–C) and umbilical vein minimal and maximal velocities (Fig. 3D–E) were not significantly different between P0 and WT. Umbilical artery maximal velocity was decreased following SC treatment in WT only (P<0.05). All other blood flow measurements were unaffected by SC treatment.

Unidirectional Maternofetal Clearance of 14C-MeAIB Across the Intact Placenta (MeAIBKmf)

MeAIBKmf, per gram placenta (Fig. 4A), was significantly higher in P0 versus WT (P<0.001) independent of treatment. There was no significant difference between non-treated and SC groups for either WT or P0 mice. When expressed per gram of fetus (Fig. 4B), MeAIBKmf was significantly higher in P0 versus WT (P<0.001) independent of treatment but not significantly different between treatment groups for either WT or P0. When assessed as MeAIB clearance (i.e. per whole placenta, Fig. 4C), there was no significant difference between P0 and WT. However, clearance of MeAIBKmf was significantly higher following SC treatment in P0 mice only (P<0.05).


The data presented here demonstrate that, in rejection of the null hypothesis, SC increased fetal growth in FGR-affected (P0) mice. There was also a trend towards increased placental weight in SC-treated versus untreated P0 mice. Whilst the mechanism underlying this apparent increase in P0 placental weight remains unclear, a larger placenta ultimately affords increased nutrient delivery to the fetus and increased fetal weight.

Untreated WT and P0 fetal weights were comparable with previous observations [22][24], [32] and confirmed the P0 FGR phenotype in the mice used in this study. Although there was an increase in fetal weight in SC-treated compared with untreated P0 fetuses, the weight of these fetuses remained lower than in WT mice. Thus, SC treatment failed to fully correct fetal weight in FGR mice. However, in order for a treatment for FGR to be clinically relevant, increasing fetal weight above the 5th centile of weights (and certainly above the 10th centile, the small for gestational age threshold) is likely to lead to improved short and long-term outcomes [3], [4], [38]. In this context, SC treatment resulted in 49% of P0 fetuses being above the 5th centile of WT control weights compared with just 25% in untreated P0 mice, again suggesting that the treatment is clinically valuable. Whilst potentially clinically valuable, it should be pointed out that treatment of SC in this model began at E 12.5, prior to the onset of FGR. The fact that the P0 mouse demonstrates a smaller placenta prior to this FGR suggests that, extrapolating these data into the clinic, treatment may be best directed to those pregnancies where a small placenta is apparent. Although accurate estimation of placental size via ultrasound has proven difficult to date, more recent use of 3D power Doppler has shown more encouraging results [39].

Interestingly, SC treatment failed to increase fetal weight in the WT C57Bl/6J pups, in contrast with previous reports in sheep [14], mice [13] and rats [40], [41] which suggest an increased fetal weight in control fetuses from SC-treated mothers.

SC treatment resulted in an increased P0 fetal abdominal circumference, consistent with the increased fetal weight observed in P0 mice. These data accord with previous studies in human [17] and mouse [13] pregnancy which have both reported an increased fetal abdominal circumference in FGR following SC administration. Asymmetric FGR is characterized by a reduced abdominal circumference and presents more commonly as a feature of late-onset FGR, associated with placental insufficiency [21], [42]. We have demonstrated previously that the P0 mouse is a model of late-onset FGR [23], [32] and thus the increase in abdominal circumference following SC treatment shown here may be translated to the human. SC has yet to be tested in this cohort clinically, with the only study thus far on those with severe early onset FGR [17]. It must be emphasized however that in the current study, SC was administered over the final week of pregnancy in mice, roughly equivalent to the end of the second trimester onwards in humans. Thus, therapies targeted to late-onset FGR first need their effectiveness tested over the final 2 or 3 days of gestation in appropriate mouse models. Abdominal circumference was also increased in WT treated mice, despite the lack of an effect on fetal weight. Whilst increasing abdominal circumference in an already appropriately grown fetus may not be a desirable outcome, it is unlikely that SC would be administered prophylactically in the clinic.

Blood flow velocity, estimated by ultrasound biomicroscopy, confirmed the absence of an abnormal vascular phenotype in the P0 knockout mouse, consistent with our previous myography data [27]. The decreased umbilical artery maximal velocity seen in treated versus untreated WT mice was unexpected and is worthy of further investigation, although it is important to note that this difference was not observed in the P0 mouse.

SC only increased placental weight (P = 0.056) in the current study in P0 mice, with WT placental weight unaltered. This is in contrast with studies suggesting that SC increased placental weight in control Wistar rats following long-term administration [40], [41] but in agreement with recent work in mice which failed to detect any differences in placental weight following SC treatment [13]. Most other published in vivo studies examining the effectiveness of SC in FGR failed to report placental weight, and this does require further investigation.

In order to assess whether the trend towards increased P0 placental size led to subsequent increases in nutrient delivery to the fetus, we assessed placental transport by measurement of the well characterised system A amino acid transport system. System A has been shown to be altered in placentas associated with FGR, both in human [34], [35] and in rodent models [22], [31], [43], [44]. The MeAIBKmf, per gram of placenta, was comparable between treated and untreated mice, and so the apparently larger P0 placenta following SC treatment significantly increased total MeAIB delivery to the fetus. This was particularly evident in the SC treated P0 mice. This increased MeAIB delivery affords a potential mechanism for the increased P0 fetal weight observed. This also shows that placental efficiency, in terms of System A transport, was unaffected by SC treatment, a fact supported by the lack of a difference in the fetal:placental weight ratio in the SC treated groups. The mechanism behind the trend towards increased P0 placental weight following SC treatment is currently unknown. Evidence suggests that SC, and other PDE-5 inhibitors such as Taladafil, are able to promote angiogenesis via cGMP in non-placental vascular beds [45][47] and future placental vascular casting studies may be useful in this regard. In addition, little is known regarding the effects of SC on trophoblast proliferation. Both of these possibilities are currently being investigated.

This study confirms and extends the evidence that SC treatment may be valuable in FGR. Importantly, the data here show that SC can improve fetal growth in a mouse model of FGR without any detectable placental vascular dysfunction. This is particularly relevant as a significant percentage of FGR cases in the clinic do not demonstrate aberrant uteroplacental blood flow, suggesting that SC may have therapeutic value in a larger than expected population of FGR cases.

We are grateful to Prof Sandra Davidge, Dr Joanna Stanley, Dr Edward Johnstone and Dr Elizabeth Cottrell for helpful discussions and thank the staff of the Biological Services Facility, University of Manchester. Sildenafil citrate was kindly provided by Pfizer.

1. Miller J,, Turan S,, Baschat AA, (Year: 2008) Fetal growth restriction. Semin Perinatol32: 274–28018652928
2. Growth_Restriction_Intervention_Trial (Year: 2003) A randomised trial of timed delivery for the compromised preterm fetus: short term outcomes and Bayesian interpretation. BJOG110: 27–3212504932
3. Barker DJ,, Bull AR,, Osmond C,, Simmonds SJ, (Year: 1990) Fetal and placental size and risk of hypertension in adult life. BMJ301: 259–2622390618
4. Barker DJ,, Osmond C, (Year: 1988) Low birth weight and hypertension. Br Med J297: 134–1353408942
5. Osmond C,, Kajantie E,, Forsen TJ,, Eriksson JG,, Barker DJ, (Year: 2007) Infant growth and stroke in adult life: the Helsinki birth cohort study. Stroke38: 264–27017218608
6. Baschat AA, Galan HL, Ross MG, Gabbe SG (2007) Intrauterine Growth Restriction. In: Gabbe SG, Niebyl JR, Simpson JL, editors. Obstetrics Normal and Problem Pregnancies. Philadelphia: Churchill Livingstone Elsevier. 771–814.
7. Bernstein IM,, Horbar JD,, Badger GJ,, Ohlsson A,, Golan A, (Year: 2000) Morbidity and mortality among very-low-birth-weight neonates with intrauterine growth restriction. The Vermont Oxford Network. Am J Obstet Gynecol182: 198–20610649179
8. Resnik R, (Year: 2002) Intrauterine growth restriction. Obstet Gynecol99: 490–49611864679
9. Fisk NM,, Atun R, (Year: 2008) Market failure and the poverty of new drugs in maternal health. PLoS Med5: e2218215109
10. Boolell M,, Allen MJ,, Ballard SA,, Gepi-Attee S,, Muirhead GJ,, et al. (Year: 1996) Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res8: 47–528858389
11. Wareing M,, Myers JE,, O’Hara M,, Baker PN, (Year: 2005) Sildenafil citrate (Viagra) enhances vasodilatation in fetal growth restriction. J Clin Endocrinol Metab90: 2550–255515713717
12. Villanueva-Garcia D,, Mota-Rojas D,, Hernandez-Gonzalez R,, Sanchez-Aparicio P,, Alonso-Spilsbury M,, et al. (Year: 2007) A systematic review of experimental and clinical studies of sildenafil citrate for intrauterine growth restriction and pre-term labour. J Obstet Gynaecol27: 255–25917464805
13. Stanley JL,, Andersson IJ,, Poudel R,, Rueda-Clausen CF,, Sibley CP,, et al. (Year: 2012) Sildenafil citrate rescues fetal growth in the catechol-o-methyl transferase knockout mouse model. Hypertension59: 1021–102822392899
14. Satterfield MC,, Bazer FW,, Spencer TE,, Wu G, (Year: 2010) Sildenafil citrate treatment enhances amino acid availability in the conceptus and fetal growth in an ovine model of intrauterine growth restriction. J Nutr140: 251–25820018809
15. Miller SL, Loose JM, Jenkin G, Wallace EM (2009) The effects of sildenafil citrate (Viagra) on uterine blood flow and well being in the intrauterine growth-restricted fetus. Am J Obstet Gynecol 200: 102 e101–107.
16. Nassar AH,, Masrouha KZ,, Itani H,, Nader KA,, Usta IM, (Year: 2012) Effects of sildenafil in Nomega-nitro-L-arginine methyl ester-induced intrauterine growth restriction in a rat model. Am J Perinatol29: 429–43422399207
17. von Dadelszen P,, Dwinnell S,, Magee LA,, Carleton BC,, Gruslin A,, et al. (Year: 2011) Sildenafil citrate therapy for severe early-onset intrauterine growth restriction. BJOG118: 624–62821392225
18. Cnossen JS,, Morris RK,, ter Riet G,, Mol BW,, van der Post JA,, et al. (Year: 2008) Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis. CMAJ178: 701–71118332385
19. Marconi AM,, Ronzoni S,, Vailati S,, Bozzetti P,, Morabito A,, et al. (Year: 2009) Neonatal morbidity and mortality in intrauterine growth restricted (IUGR) pregnancies is predicated upon prenatal diagnosis of clinical severity. Reprod Sci16: 373–37919087980
20. Niknafs P,, Sibbald J, (Year: 2001) Accuracy of single ultrasound parameters in detection of fetal growth restriction. Am J Perinatol18: 325–33411607850
21. Chang TC,, Robson SC,, Spencer JA,, Gallivan S, (Year: 1994) Prediction of perinatal morbidity at term in small fetuses: comparison of fetal growth and Doppler ultrasound. Br J Obstet Gynaecol101: 422–4278018615
22. Constancia M,, Hemberger M,, Hughes J,, Dean W,, Ferguson-Smith A,, et al. (Year: 2002) Placental-specific IGF-II is a major modulator of placental and fetal growth. Nature417: 945–94812087403
23. Dilworth MR,, Kusinski LC,, Cowley E,, Ward BS,, Husain SM,, et al. (Year: 2010) Placental-specific Igf2 knockout mice exhibit hypocalcemia and adaptive changes in placental calcium transport. Proc Natl Acad Sci U S A107: 3894–389920133672
24. Sibley CP,, Coan PM,, Ferguson-Smith AC,, Dean W,, Hughes J,, et al. (Year: 2004) Placental-specific insulin-like growth factor 2 (Igf2) regulates the diffusional exchange characteristics of the mouse placenta. Proc Natl Acad Sci U S A101: 8204–820815150410
25. Mayhew TM,, Manwani R,, Ohadike C,, Wijesekara J,, Baker PN, (Year: 2007) The placenta in pre-eclampsia and intrauterine growth restriction: studies on exchange surface areas, diffusion distances and villous membrane diffusive conductances. Placenta28: 233–23816635527
26. Mayhew TM,, Ohadike C,, Baker PN,, Crocker IP,, Mitchell C,, et al. (Year: 2003) Stereological investigation of placental morphology in pregnancies complicated by pre-eclampsia with and without intrauterine growth restriction. Placenta24: 219–22612566249
27. Kusinski LC,, Dilworth MR,, Baker PN,, Sibley CP,, Wareing M,, et al. (Year: 2011) System A activity and vascular function in the placental-specific Igf2 knockout mouse. Placenta32: 871–87621851977
28. Constancia M,, Dean W,, Lopes S,, Moore T,, Kelsey G,, et al. (Year: 2000) Deletion of a silencer element in Igf2 results in loss of imprinting independent of H19. Nat Genet26: 203–20611017078
29. Lukowski R,, Weinmeister P,, Bernhard D,, Feil S,, Gotthardt M,, et al. (Year: 2008) Role of smooth muscle cGMP/cGKI signaling in murine vascular restenosis. Arterioscler Thromb Vasc Biol28: 1244–125018420996
30. Walker DK,, Ackland MJ,, James GC,, Muirhead GJ,, Rance DJ,, et al. (Year: 1999) Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica29: 297–31010219969
31. Kusinski LC,, Stanley JL,, Dilworth MR,, Hirt CJ,, Andersson IJ,, et al. (Year: 2012) eNOS knockout mouse as a model of fetal growth restriction with an impaired uterine artery function and placental transport phenotype. Am J Physiol Regul Integr Comp Physiol303: R86–9322552791
32. Dilworth MR,, Kusinski LC,, Baker BC,, Renshall LJ,, Greenwood SL,, et al. (Year: 2011) Defining fetal growth restriction in mice: A standardized and clinically relevant approach. Placenta32: 914–91621889207
33. Constancia M,, Angiolini E,, Sandovici I,, Smith P,, Smith R,, et al. (Year: 2005) Adaptation of nutrient supply to fetal demand in the mouse involves interaction between the Igf2 gene and placental transporter systems. Proc Natl Acad Sci U S A102: 19219–1922416365304
34. Glazier JD,, Cetin I,, Perugino G,, Ronzoni S,, Grey AM,, et al. (Year: 1997) Association between the activity of the system A amino acid transporter in the microvillous plasma membrane of the human placenta and severity of fetal compromise in intrauterine growth restriction. Pediatr Res42: 514–5199380446
35. Shibata E,, Hubel CA,, Powers RW,, von Versen-Hoeynck F,, Gammill H,, et al. (Year: 2008) Placental system A amino acid transport is reduced in pregnancies with small for gestational age (SGA) infants but not in preeclampsia with SGA infants. Placenta29: 879–88218718657
36. Flexner LB,, Pohl HA, (Year: 1941) The transfer of radioactive sodium across the placenta of the rabbit. Am J Physiol134: 344–349
37. Bond H,, Dilworth MR,, Baker B,, Cowley E,, Requena Jimenez A,, et al. (Year: 2008) Increased maternofetal calcium flux in parathyroid hormone-related protein-null mice. J Physiol586: 2015–202518258656
38. Acolet D, Springett A, Golightly S (2006) Confidential Enquiry Into Maternal and Child Health: Perinatal mortality. CEMACH: 7pp.
39. Pomorski M,, Zimmer M,, Florjanski J,, Michniewicz J,, Wiatrowski A,, et al. (Year: 2012) Comparative analysis of placental vasculature and placental volume in normal and IUGR pregnancies with the use of three-dimensional Power Doppler. Arch Gynecol Obstet285: 331–33721744006
40. Pellicer B,, Herraiz S,, Cauli O,, Rodrigo R,, Asensi M,, et al. (Year: 2011) Haemodynamic effects of long-term administration of sildenafil in normotensive pregnant and non-pregnant rats. BJOG118: 615–62321244618
41. Herraiz S,, Pellicer B,, Serra V,, Cauli O,, Cortijo J,, et al. (Year: 2012) Sildenafil citrate improves perinatal outcome in fetuses from pre-eclamptic rats. BJOG119: 1394–140222827567
42. Cox P,, Marton T, (Year: 2009) Pathological assessment of intrauterine growth restriction. Best Pract Res Clin Obstet Gynaecol23: 751–76419854107
43. Jansson N,, Pettersson J,, Haafiz A,, Ericsson A,, Palmberg I,, et al. (Year: 2006) Down-regulation of placental transport of amino acids precedes the development of intrauterine growth restriction in rats fed a low protein diet. J Physiol576: 935–94616916910
44. Stanley JL, Andersson IJ, Hirt CJ, Moore L, Dilworth MR, et al. . (2012) Effect of the anti-oxidant tempol on fetal growth in a mouse model of fetal growth restriction. Biol Reprod 87: 25, 21–28.
45. Ladha F,, Bonnet S,, Eaton F,, Hashimoto K,, Korbutt G,, et al. (Year: 2005) Sildenafil improves alveolar growth and pulmonary hypertension in hyperoxia-induced lung injury. Am J Respir Crit Care Med172: 750–75615947285
46. Pyriochou A,, Zhou Z,, Koika V,, Petrou C,, Cordopatis P,, et al. (Year: 2007) The phosphodiesterase 5 inhibitor sildenafil stimulates angiogenesis through a protein kinase G/MAPK pathway. J Cell Physiol211: 197–20417226792
47. Zhang L,, Zhang Z,, Zhang RL,, Cui Y,, LaPointe MC,, et al. (Year: 2006) Tadalafil, a long-acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke. Brain Res1118: 192–19816959227


[Figure ID: pone-0077748-g001]
doi: 10.1371/journal.pone.0077748.g001.
Figure 1  Study design.

Number of litters and pups (WT and P0) in each group and each study arm are demonstrated. Sildenafil citrate (0.4 mg/ml in drinking water) was administered from embryonic day (E) 12.5 and all measurements were taken at E 18.5. For ultrasound biomicroscopy, due to necessity to ID pups accurately immediately after scanning (as WT and P0 exist within the same litter), not all pups underwent ultrasound biomicroscopy (numbers in parentheses are those that did.).

[Figure ID: pone-0077748-g002]
doi: 10.1371/journal.pone.0077748.g002.
Figure 2  Fetal and placental weights following Sildenafil citrate treatment.

Fetal weights (A,B), placental weights (C) and fetal:placental weight ratios (D) at embryonic day 18.5 in wild-type (WT) and placental-specific Igf2 knockout (P0) mice. Pregnant dams were allowed access to water with (N = 19 litters) or without (N = 23 litters) Sildenafil citrate (SC, 0.4 mg/ml). In figures 2A,C and D, Mean+SEM is shown. Figure 2B demonstrates fetal weights as frequency distribution curves for individual pups; WT control (black solid curve), WT SC (black dashed curve), P0 control (grey solid curve) and P0 SC (grey dashed curve). Vertical dashed line denotes the 5th centile of WT control fetal weights (1.03 g). Individual pup n’s: WT control n = 95, WT SC n = 82, P0 control n = 88, P0 SC n = 77. Statistical analyses of genotype and treatment were performed by Generalized Linear Mixed Models test followed by Sequential Sidak multiple comparisons test. ***P<0.001 WT v P0, P<0.05 P0 water v P0 SC group.

[Figure ID: pone-0077748-g003]
doi: 10.1371/journal.pone.0077748.g003.
Figure 3  Haemodynamic parameters of umbilical vasculature following ultrasound biomicroscopy.

Mean+SEM. Individual pup n’s: WT control n = 16, WT SC n = 11, P0 control n = 11, P0 SC n = 13 from 6 untreated and treated litters. Statistical analyses were performed by Generalized Linear Mixed Models test followed by Sequential Sidak multiple comparisons test. This assessed effects of genotype and treatment. P<0.05 WT water v WT SC group.

[Figure ID: pone-0077748-g004]
doi: 10.1371/journal.pone.0077748.g004.
Figure 4  Unidirectional maternofetal clearance of methylaminoisobutyric acid (MeAIBKmf) following Sildenafil citrate treatment.

MeAIBKmf expressed per gram placental weight (measure of placental efficiency, A), per gram fetal weight (measure of appropriate delivery of MeAIB to the fetus, B) and total MeAIB clearance, C. Pregnant dams were allowed access to water with (N = 8 litters, 36 WT and 28 P0 pups) or without (N = 8 litters, 35 WT and 32 P0 pups) Sildenafil citrate (SC, 0.4 mg/ml). Mean+SEM. Statistical analyses of genotype and treatment were performed by Generalized Linear Mixed Models test followed by Sequential Sidak multiple comparisons test. ***P<0.001 WT v P0, P<0.05 P0 water v P0 SC group.

[TableWrap ID: pone-0077748-t001] doi: 10.1371/journal.pone.0077748.t001.
Table 1  Fetal anthropometric measurements following Sildenafil citrate (SC) treatment.
WATER (N = 14 litters) SC TREATED (N = 11 litters)
WT (n = 56) P0 (n = 53) WT (n = 46) P0 (n = 49)
Crown:rump length (mm) Genotype***Treatment NS 28.9±0.3 26.6±0.3 29.1±0.4 27.1±0.3
Abdominal circ (mm) Genotype*** Treatment** 26.3±0.3 23.1±0.4 27.2±0.3a 24.3±0.5b
Head circ (mm) Genotype* Treatment NS 24.8±0.2 24.1±0.2 24.8±0.1 24.6±0.1

Crown:rump length, abdominal and head circumference of WT and P0 fetuses at E18.5 from untreated water (control) and SC treated dams. Mean ± SEM. Statistical analyses were performed by Generalized Linear Mixed Models test followed by Sequential Sidak multiple comparison test. This assessed effects of genotype and treatment.




aP<0.01 versus WT control;

bP<0.01 versus P0 control.

Article Categories:
  • Research Article

Previous Document:  The Vitamin D Receptor Agonist BXL-01-0029 as a Potential New Pharmacological Tool for the Treatment...
Next Document:  Calcium/Calcineurin Synergizes with Prostratin to Promote NF-?B Dependent Activation of Latent HIV.